Leheup B, Schaeffer L, Jeandel C, Pierson M
Service de médecine infantile I, Hôpital d'Enfants, Vandoeuvre-lès-Nancy, France.
Pediatrie. 1992;47(4):291-5.
The final adult height in patients with growth deficiency treated with growth hormone has been shown to depend upon pubertal development. This is mainly related to the shortening of puberty duration and accelerated bone maturation. A long acting analogue of gonadoliberin, Trp-6-GnRH, has been given to 17 patients with isolated growth hormone deficiency in order to delay pubertal progression. In seven of these patients, GH treatment and the analogue of Gn-RH were initiated simultaneously. The other 10 patients had been treated for more than one year with hGH at the onset of the analogue. Mean duration of treatment was 17 months. Annual growth rate was low in all cases. Statural progression was parallel to the delayed bone maturation without change in the ratio of statural maturation to bone maturation. No significant change in height prediction was observed after the combined treatment. Combination of the long-acting analogue of gonadoliberin, Trp-6-Gn-RH, with growth hormone in GH-deficient patients does not seem to be an appropriate way to improve final height after the onset of spontaneous puberty.
生长激素治疗生长缺陷患者的最终成人身高已被证明取决于青春期发育。这主要与青春期持续时间缩短和骨骼成熟加速有关。已对17例孤立性生长激素缺乏患者给予长效促性腺激素释放激素类似物Trp-6-GnRH，以延缓青春期进程。其中7例患者同时开始生长激素治疗和Gn-RH类似物治疗。另外10例患者在开始使用类似物时已接受hGH治疗一年以上。平均治疗持续时间为17个月。所有病例的年生长率都很低。身高进展与骨骼成熟延迟平行，身高成熟与骨骼成熟的比例没有变化。联合治疗后身高预测无显著变化。在自发性青春期开始后，将长效促性腺激素释放激素类似物Trp-6-Gn-RH与生长激素联合用于生长激素缺乏患者，似乎不是提高最终身高的合适方法。
